TG Therapeutics (TGTX)
(Delayed Data from NSDQ)
$17.79 USD
-0.16 (-0.89%)
Updated Jun 28, 2024 04:00 PM ET
After-Market: $17.82 +0.03 (0.17%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Brokerage Reports
TG Therapeutics, Inc. [TGTX]
Reports for Purchase
Showing records 221 - 240 ( 277 total )
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Nice PI3K Deal for INFI; TGTX Has Strong Leverage with ''1202
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
How I Learned To Stop Worrying & Love Combo Trials
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
''1202 Safety Benefit vs Zydelig; Plus, Docs Want ''Em All; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
2Q14 Results; ASH Should be Fun this Year; Reiterate Focus Pick
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
A Midsummer''s Night Treat; Reiterate Focus Pick; Target Upped to $25
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
TG and Ligand Partner Up to Grow Pipeline; Reiterate Focus Pick
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Sweet Imbruvica Combo Data; Target Raised to $20; Reiterate Focus Pick
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Expecting to Say Yee-Haa at EHA; Focus on ''1101/Imbruvica Combo
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
ASCO Impresses; KOL Enthusiasm Clear; Reiterate Focus Pick
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J